Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 3,915 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Glaucoma
Interventions: Rocklatan 0.02%-0.005% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Eye Centers of Southeast Texas; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Beaumont, Texas

Conditions: Glaucoma
Interventions: Retroject Device, ethacrynic acid injection, balanced salt solution; Device · Drug
Lead sponsor: Molly Walsh; Other
Eligibility: 55 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pre-hypertension, JNC 7 Stage I Hypertension
Interventions: Allopurinol, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
Interventions: paricalcitol, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension, Dyslipidemias
Interventions: DASH diet counseling; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Pulmonary Arterial Hypertension
Interventions: Esuberaprost, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more

Conditions: Hypertension
Interventions: Self-affirmation intervention; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tadalafil, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more

Conditions: Hypertension
Interventions: Device under test evaluation against references; Device
Lead sponsor: Aktiia SA; Industry
Eligibility: 22 Years to 59 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Osteoarthritis, Hypertension
Interventions: naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 57
States / cities: Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 81
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 57 more

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more

Conditions: Hypertension, Uncontrolled Hypertension
Interventions: iloperidone, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more

Conditions: Pulmonary Hypertension
Interventions: 11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Hypertension
Interventions: SMART; Behavioral
Lead sponsor: Colorado Center for Chronic Care Innovations, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Westminster, Colorado

Conditions: Alveolitis, Fibrosing, Fibrosis, Pulmonary, Hypertension, Pulmonary
Interventions: sildenafil; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Preeclampsia
Interventions: Ravulizumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Portal Hypertension, Chronic Liver Disease
Interventions: ARFI ultrasound; Device
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions: Renal Denervation using the Symplicity Renal Denervation System, Sham Renal Denervation, Renal Angiography; Device · Other
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina

Conditions: Pulmonary Hypertension
Interventions: Cardiac Resynchronization Therapy (CRT); Device
Lead sponsor: Dr. Daniel P Morin, MD MPH FHRS; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Diabetes, Hypertension
Interventions: Financial Incentive Group I, Financial Incentive Group II; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Type 2 Diabetes, Metabolic Syndrome, Smoking, High Cholesterol, PreDiabetes, Prehypertension
Interventions: Project WHADE: A Partner-Based Physical Activity Program for Women; Behavioral
Lead sponsor: Rowan University; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Glassboro, New Jersey

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Hypertension
Interventions: mGlide; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Rocklatan vs Latanoprost Post-DSLT

Novel Drug Delivery Technique Via Retroject Device

Center of Research Translation (CORT) Project 2

Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

The Association Between the Use of Complementary and Alternative Medicine and Medication Adherence in Hypertensive African-Americans

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

OBPM_PANDA2026: Evaluation of the Performance and Safety of the Aktiia Periodic Optical Blood Pressure Monitoring Device

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

The Short-Term Effect of a Technology Driven Weight Control (SMART) Program for Obese Adults

Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)

Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4

Cardiac Resynchronization Therapy in Pulmonary Hypertension

Way to Health, Healthy Measures

Project WHADE: A Partner-Based Physical Activity Program for Women

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management